Targeting APRIL to slow progression of IgA nephropathy
- PMID: 38012265
- DOI: 10.1038/s41581-023-00794-x
Targeting APRIL to slow progression of IgA nephropathy
Comment on
-
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. N Engl J Med. 2024. PMID: 37916620 Free PMC article. Clinical Trial.
References
Original article
-
- Mathur, M. et al. A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N. Eng. J. Med. https://doi.org/10.1056/NEJMoa2305635 (2023) - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
